Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 6/20 | 0.46 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | BAX | Q07812 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL704145 | 0.87 | CA4 (0.37) | ESR2ESR1LTA4HALDH1A1CA4 | |
| SCHEMBL27600931 | 0.84 | CA4 (0.46) | LTA4HALDH1A1CYP3A4LMNACYP1A2 | |
| SCHEMBL7092637 | 0.83 | CYP3A4 (0.42) | ESR2ESR1ALDH1A1CYP3A4LMNA | |
| SCHEMBL9270393 | 0.83 | DGAT1 (0.38) | — | |
| SCHEMBL7424773 | 0.82 | MAOA (0.44) | ALDH1A1CYP3A4MEN1KMT2ATDP1 | |
| SCHEMBL17233741 | 0.82 | SMN1; SMN2 (0.46) | ESR2ESR1ALDH1A1CYP3A4LMNA | |
| SCHEMBL20594005 | 0.82 | — | — | |
| SCHEMBL6058734 | 0.82 | ALDH1A1 (0.37) | ALDH1A1LMNASLC6A2SLC6A3MEN1 | |
| SCHEMBL6698974 | 0.81 | CA2 (0.49) | CA1CA2CA4CA14 | |
| SCHEMBL12919164 | 0.81 | CA1 (0.46) | KMT2ACA1CA2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-6537994-B2 | For therapy and prophylaxis of metabolic disorders related to insulin resistance or hyperglycemia, atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination | WYETH | 2003-03-25 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6506901-B2 | 1-(9H-Carbazol-4-yloxy)-3-((1-(7-trifluoromethyl-quinolin-4-yl) -piperidin-4-lmethyl)-amino)-propan-2-ol, for example; treating diabetes, urinary continence, atherosclerosis, gastrointestinal disorders, glaucoma | WYETH | 2003-01-14 | — | — | US | disclosed |
| US-6458817-B1 | AROMATIC SUBSTITUTED SUFURE OR SULFOXIDE OR SULFONE DERIVATIVES CONTAINING SECONDAY AMINE AND HYDROXY GROUPS ARE USEFUL IN TREATNG METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN MAMMALS | WYETH | 2002-10-01 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020040023-A1 | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-04 | — | — | US | disclosed |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-28 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020022638-A1 | Heterocyclic Beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-21 | — | — | US | disclosed |
| EP-0553107-B1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARM INC (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5955501-A | DERIVED FROM PHORBOIDS OF THE DITERPENE- AND BENZOLACTAM-CLASSES. | PROCYON PHARMACEUTICALS, INC. (US) | 1999-09-21 | — | — | US | disclosed |
| US-5891870-A | ANTIINFLAMMATORY AGENTS USING BENZODITERPENES AND BENZOLACTAMS | PROCYON PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5891906-A | Polyacetate-derived phorboids having anti-inflammatory and other uses | PROCYON PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5886019-A | REPLACEMENT OF HYDROXYMETHYL OR-ETHYL GROUP ON TRICYCLIC AROMATIC HETEROCYCLIC COMPOUNDS HAVING INDOLE, INDENE, BENZOFURAN OR BENZOTHIOPHENE SKELETON; ANTIINFLAMMATORY, ANTIVIRAL | PROCYON PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5750568-A | DITERPENE PHORBOIDS | PROCYON PHARMACEUTICALS, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5716968-A | ANTIINFLAMMATORY AGENTS; VIRICIDE | PROCYON PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5643948-A | ANTIINFLAMMATORY, ANTICANCER | PROCYON PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0553107-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARMACEUTICALS, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992002484-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | ALDER RESEARCH CENTER LIMITED PARTNERSHIP (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ESR2 481/4885ESR1 2127/4885LTA4H 2156/4885 |
| US-20020037907-A1 | Substituted 2- (S) -hydroxy-3- (piperidin-4-yl-methylamino) -propyl ethers and substituted 2-aryl-2- (R) - hydroxy-1- (piperidin-4-yl-methyl) -ethylamine beta-3 adrenergic receptor agonists | GPR119, ADRB1, ADRB2 | ESR2 119/4885ESR1 660/4885LTA4H 2418/4885 |
| US-20020040023-A1 | Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists | ADRB1, ADRB3, GPR119 | ESR2 384/4885ESR1 1767/4885LTA4H 1841/4885 |
| US-20020022638-A1 | Heterocyclic Beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | ESR2 507/4885ESR1 2009/4885LTA4H 2099/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | ESR2 563/4885ESR1 1765/4885LTA4H 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.